A growing number of diagnostics developers have set out to address the challenge of meeting the nation’s need for more COVID-19 tests. Here we profile five companies that have answered that challenge by working to bring new assays, with new technologies, to patients.
The study initially aims to enroll 20,000 people who are currently, or were previously, in intensive care with severe COVID-19 disease, as well as 15,000 infected individuals who suffered only mild or moderate symptoms.
Biguanides are primarily known for their ability to lower blood sugar, and metformin, now one of the most commonly prescribed medications in the U.S., has been available to treat diabetes since the 1950s.
Researchers at Mount Sinai have developed a unique algorithm that can rapidly detect COVID-19 based on how lung disease looks in computed tomography (CT scans) of the chest, in combination with patient information including symptoms, age, bloodwork, and possible contact with someone infected with the virus.
The guidelines—based on published and preliminary data—are posted online at covid19treatmentguidelines.nih.gov and will be updated regularly as new data from peer-reviewed scientific literature and other authoritative information emerges.
Combination of Genentech’s Actemra, Gilead’s Remdesivir Enters Phase III Trial for Treatment of Severe...
The global randomized, double-blind, placebo-controlled Phase III trial—to be called REMDACTA—will compare the safety and efficacy of Actemra plus remdesivir to placebo plus remdesivir in severe COVID-19 patients receiving standard of care.
The study defined recovery as being discharged from the hospital or being medically stable enough to be discharged from the hospital. The median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo
COVID-19 infects cells by binding to the ACE2 protein, found on the surface of cells in the lungs, cardiovascular system, kidneys, and in the gut. The research says the biggest predictor of high ACE2 levels is being male.
The NIAID-sponsored clinical trial is a large randomized, controlled clinical trial to determine whether hydroxychloroquine, given in combination with the antibiotic azithromycin, can prevent hospitalization and death due to COVID-19.
The researchers demonstrated that ketone bodies, which are molecular byproducts that gives the ketogenic diet its name, directly change levels of certain types of gut bacteria, which led to reduced levels of intestinal pro-inflammatory immune cells.
Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment.
Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected.
Smoking increases the gene expression of ACE2—the protein that binds SARS-CoV-2. The study suggests that prolonged smoking could cause an increase of the ACE2 protein in the lungs, possibly resulting in a higher rate of morbidity in patients.
The Phase I data showed that all 45 participants across the study’s three dose levels produced antibodies of the virus by day 15 following dosing, with eight people in two of the dose levels reaching or exceeding neutralizing antibody titers generally seen in convalescent sera.
The results indicate that while the DNA of individuals with autism may harbor different alterations, the activity of these genes is similar in people with the disorder, and differs from that of the same genes in the brains of people without autism.
Six vaccinated macaques and three unvaccinated controls were exposed to the virus a month after receiving one dose of the vaccine. The team saw a significantly lower number of viral particles in liquid and fluid taken from the lungs of the animals in the study that had been vaccinated compared with the controls.
The genome-wide association study compared the DNA samples and clinical data of healthy thin individuals with normal-weight individuals, in the search for genetic variants linked with thinness. The results highlighted genetic variants in the ALK gene that were specific to the thin individuals.
The study could signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women.
While the decrease was most pronounced in lung cancer testing and diagnoses, the oncology tracker also recorded reduced diagnosis rates in colorectal, ovarian, and breast cancers over the same period.
The app leverages large cancer data repositories to calculate mortality risks associated with immediate compared with delayed treatment and also takes into account age, cancer type, treatment plan, and presence of other comorbidities.
The reported study data have led to the formation of a new start-up brain cancer immunotherapy company, Empirica Therapeutics, which aims to start clinical trials of the CD133-targeting CAR-T-cell therapy in recurrent glioblastoma patients by 2022.
Moderna said the Phase II study of mRNA-1273 is expected to start soon after the FDA reviewed the company’s IND application for the vaccine candidate.
The research showed that both mouse and human carriers of the APOE4 gene variant had less melanoma progression and metastasis compared with those who had the APOE2 gene variant, as well as a better response to cancer immunotherapy.
The findings could one day lead to advanced screening methods to discern who is at greatest risk of developing disease, and could help reveal new genetic targets for research and drug development.
While miRNAs can regulate many genes, they have been shown to have a strong impact on cancer development and on processes such as cancer drug resistance.